OnCo
trialsTrialPositive

CLARINET

Lanreotide more than halved the risk of progression in gut and pancreatic neuroendocrine tumours.

PFS median not reached vs 18.0 months (HR 0.47); 24-month PFS 65% vs 33%. Basis for lanreotide's antiproliferative label.

Setting
Non-functioning enteropancreatic NETs, grade 1-2: lanreotide 120 mg vs placebo
Phase
Phase 3
Sponsor
Ipsen
Registry
Headline result
PFS HR 0.47.
Reported
2014
Enrolled
204

Outcomes

1top
In plain words
What these results mean for people, not percentages
204 people took part
Progression-free survivalprimarysurrogate endpoint
  • Median 18 months with Placebo.
  • Lanreotide: not reached.
  • "Not reached" means that, when the data were analysed, more than half of that group had not yet had the event, which is good news for that group.
  • A median is a midpoint: half the people did better than this and half did worse.
  • Put another way, the treated group had about 53 percent lower chance of the event at any given time (hazard ratio 0.47, likely range 0.3 to 0.73).
  • This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
  • These results apply to the people the trial enrolled: Non-functioning enteropancreatic NETs, grade 1-2: lanreotide 120 mg vs placebo. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

204 participants enrolled.

Progression-free survivalprimary
HR 0.47 (0.3–0.73) · p <0.001
Lanreotide
not reached
Placebo
18 mo

not reached

EndpointArmnValueHR (95% CI)pSource
Progression-free survivalprimaryLanreotide101not reached0.47 (0.3–0.73)<0.001
Placebo10318 months

Connected

3top